Type “OpenAI” into a brokerage app and you won’t find a share to buy. As of early November 2026, the company behind ChatGPT remains private, with no exchange listing, no ticker and no public quote. Anything presented as “OpenAI stock” is therefore something else: a fund, a private transfer, a vehicle, a token or a contract on another company.
That makes the useful question less about price and more about what a given product really gives you.
Where OpenAI stands
Three facts define the position today.
Structure. A restructuring completed in October 2025 turned the for-profit arm into OpenAI Group PBC, a public benefit corporation. The nonprofit OpenAI Foundation appoints its directors. At the time, the Foundation held about 26% and Microsoft about 27%, with employees and other investors holding the rest. Those stakes are dated, and later funding may have diluted them.
Valuation. The last completed primary round valued OpenAI at $852 billion post-money, with $122 billion of committed capital, around the end of March 2026. Forge’s secondary-market estimate implied about $894 billion on September 21. Reports describe talks about a new round at a much higher valuation, but the figures vary and that round hasn’t been reported as closed.
IPO status. OpenAI said on June 8, 2026 that it had confidentially submitted a draft registration statement to the SEC. That isn’t a listing, and a confidential draft gives the public no prospectus to read. Sam Altman said in September that the company wouldn’t go public in 2026, and press reports treat 2027 as the earliest realistic window. No date, exchange, price or ticker has been announced.
The three routes
If the question is simply does OpenAI have stock, Canborsa’s page answers that shares exist but aren’t publicly traded, then ranks three routes by accessibility. It adds that availability depends on what holders are willing to offer at any given time.
A. Listed funds (open to any investor). You buy a closed-end or venture fund in an ordinary brokerage account, with no accreditation and no company approval. OpenAI is then one holding among many, if it’s held at all. Robinhood Ventures Fund I, listed on the NYSE, said it bought $75 million of OpenAI common stock in April 2026. The Fundrise Innovation Fund (VCX) was reported to hold OpenAI as well. Holdings change, however, so check the latest report. The main hazard is the premium to net asset value. VCX reached more than 30 times its $18.97 net asset value in March 2026, days after listing.
B. Secondary marketplaces (accredited investors only). These match existing shareholders with buyers. They offer the closest thing to direct equity, at prices based on recent private sales. In return, you face accreditation checks, company transfer approval, a right of first refusal, five-figure minimums, settlement in weeks and possibly no exit until a liquidity event. In the US, accredited status generally means more than $200,000 of annual income ($300,000 jointly) or a net worth above $1 million excluding your home.
C. Employee-share vehicles (by invitation only). These are single-purpose vehicles and forward contracts tied to employee or early-investor shares. You own an interest in the sponsor’s vehicle, not the stock. They can open allocations that never reach a marketplace, and may participate in a future tender. They also add a layer between you and the cap table, usually with management fees and carry. Qualified-purchaser status is commonly required, and counsel should read the documents first.
OpenAI’s approval matters to routes B and C. In 2025, the company stated that “any transfer of OpenAI equity requires our approval.” A vehicle’s promise is only as strong as its right to the underlying shares.
How much OpenAI do you really get?
Illustrative example, not a forecast. A listed fund trades at a 40% premium, so a share with $100 of net asset value costs $140. OpenAI makes up 5% of the fund. OpenAI’s value then doubles and nothing else changes, which lifts net asset value to $105. If the premium narrows to 10%, the fund trades at $115.50. The buyer is down 17.5% even though OpenAI doubled.
Position size and entry price can matter more than the company’s news.
Products that are not on the list
Tokens. In 2025, Robinhood offered “OpenAI tokens” to users in the European Union, describing them as indirect exposure through its stake in a special purpose vehicle. OpenAI responded publicly: “These ‘OpenAI tokens’ are not OpenAI equity.” Any tokenized product should be judged by its issuer’s documents, backing and eligibility rules.
Related public companies. Microsoft and Nvidia are both investors, so their shares have a link to OpenAI. But each is a huge business in its own right, and neither stock is an OpenAI proxy.
Perpetual contracts. Canborsa’s page shows no OpenAI market. Its route comparison instead points to NVDA-PERP as the nearest live market, with up to 20x leverage, fees of 0.055% per side and USDC margin. That contract gives price exposure to Nvidia, not to OpenAI. It conveys no shares in either company, and carries funding costs and liquidation risk. A position in it is a view on Nvidia.
Rules by country
The routes above don’t travel equally. Accreditation and qualified-purchaser tests are US concepts, and other countries use their own categories for private placements. Brokers decide which funds they offer, and to whom. Canborsa’s terms shut out anyone living in, located in or incorporated in the US, plus sanctioned territories and their citizens abroad. They also make users responsible for local compliance.
European and British users face further limits on derivatives. A February 2026 ESMA statement treats perpetuals that fit the CFD definition as likely subject to national CFD measures, while the FCA’s retail ban on crypto-asset derivatives dates from January 2021.
What to watch
A public S-1 would be the real turning point, since it would bring audited numbers, share classes and a proposed ticker into the open. A filing still doesn’t guarantee a listing. Until one appears, read what any product called OpenAI stock actually gives you.
This article is for educational purposes only and is not financial advice. Leveraged derivatives and private-market investments carry a high risk of loss.